Aytu Biopharma (AYTU) Accumulated Expenses (2012 - 2026)

Aytu Biopharma (AYTU) has 15 years of Accumulated Expenses data on file, last reported at $34.3 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $34.3 million, down 17.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.3 million (down 17.87% YoY), and the FY2025 annual result was $3.1 million, down 31.96% from the prior year.
• Accumulated Expenses climbed to $34.3 million in Q1 2026 per AYTU's latest filing, from $2.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $53.5 million in Q1 2022 and troughed at $2.3 million in Q4 2025.
• A 5-year average of $29.1 million and a median of $39.4 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses soared 956.28% in 2023, then sank 94.18% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $4.1 million in 2022, then soared by 956.28% to $43.4 million in 2023, then declined by 9.31% to $39.4 million in 2024, then slumped by 94.18% to $2.3 million in 2025, then jumped by 1395.85% to $34.3 million in 2026.
• Business Quant data shows AYTU's Accumulated Expenses at $34.3 million in Q1 2026, $2.3 million in Q4 2025, and $4.0 million in Q3 2025.